$\square$ 

## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287											
Estimated average burden											
hours per response:	0.5										

1. Name and Addres <u>Neff Thomas</u>	ss of Reporting Perso	n*	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>FIBROGEN INC</u> [ FGEN ]		tionship of Reportir all applicable) Director	g Perso X	n(s) to Issuer 10% Owner
(Last) C/O FIBROGEN 409 ILLINOIS S		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/14/2016	X	Officer (give title below) Chief Executive		Other (specify below) Officer
(Street) SAN FRANCISCO	СА	94158	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ridual or Joint/Grou Form filed by On Form filed by Mo Person	e Repor	ing Person
(City)	(State)	(Zip)					

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Disposed Of (			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130. 4)
Common Stock	06/14/2016		S		13,500(1)	D	\$16.47(2)	3,466,664	D	
Common Stock	06/15/2016		S		13,500(1)	D	<b>\$16.49</b> <sup>(3)</sup>	3,453,164	D	
Common Stock								145,070	Ι	By Family Partnership
Common Stock								20,000	Ι	By Spouse
Common Stock								60,946	I	See footnote <sup>(4)</sup>

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable ar (Month/Day/Year) Month/Day/Year)		te Amount of		Amount of Derivative Securities Security Underlying (Instr. 5) Derivative Security (Instr. 3		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Shares sold pursuant to a 10b5-1 plan.

2. The shares were sold at prices ranging from \$16.21 to \$17.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. The shares were sold at prices ranging from \$16.05 to \$16.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.

#### **Remarks:**

<u>/s/ Melissa Navarro, Attorney-</u> in-fact <u>06/16/2016</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.